In-depth analysis and the VigiEye View on regulatory, pharmacovigilance, quality and market-access developments, built from the official records and linked to every source.
A closed phenobarbital review, updated MAH templates and a draft list of medically important VeDDRA terms show where EU veterinary signal management is heading.
The sepsis diagnostics firm has completed pivotal enrolment and secured a backup cartridge site, yet its $7.38M cash lasts only to Q2 2027, the same period as its planned 510(k) filing.
Lucid's Medicare payments are a reimbursement milestone with open conditions, while sister company Veris Health heads for an early-2027 FDA filing. European supply notices show the opposite problem.
DG SANTE reports positive sponsor and Member State feedback on two years of coordinated assessment for MDR/IVDR studies. Quality teams should note what the public record does not yet show.
CATS Consultants withdrew its catequentinib application on 30 October, before EMA finished re-examining a refusal recommendation. Key facts are still missing, but the procedural lessons are clear.
The final EU-language texts close a targeted phenobarbital signal procedure just as EMA revises veterinary signal tools and consults on medically important VeDDRA terms until 31 January 2027.
The EU's Article 31 review of injectable iron asks whether current risk-minimisation measures work. QPPVs should be able to answer that for their own products before a committee does.
Game Changer Products has recalled all lots of a supplement sold online since at least 2021 after FDA found hidden sildenafil and acetaminophen. No adverse events have been reported.
A supply agreement for a planned US anal cancer study is a small deal, but it lands as FDA seeks comment on early-phase solid tumour IND protocols.
Lucid Diagnostics reports full-rate Medicare payment and record October volume, yet the wider MolDX reconsideration is unresolved, so the payment signal is real but not yet a policy.
MHRA's Class 4 notice on Star Pharmaceuticals' enalapril/hydrochlorothiazide tablets is minor on its face, but it is a useful test of labelling controls and defect triage.
The MHRA has published its second quarterly performance report and letter for 2026/27. Its value depends on whether teams use it to plan, as the contrast with FDA and Health Canada signals shows.
EMA's safety committee will assess hypophosphataemia, osteomalacia and whether current risk-minimisation measures for injectable iron work, a review covering the whole class.
FDA's NAION order covers every GLP-1 receptor agonist. QPPVs should stop treating class-wide safety as a competitor's problem and build standing class-level surveillance.
This week's records show regulators bridging gaps with imports, special programmes and allocation. Pricing and access teams that stop at the listing are measuring the wrong thing.
DG SANTE, the EMA and Singapore's HSA will exchange information on medicines and devices with immediate effect. Scope and safety content are not yet public, so PV teams should watch for detail.
The agency's draft covers first-in-human and limited-experience oncology protocols but excludes haematologic malignancies. Sponsors have until 11 January 2027 to comment.
The Commission's One Health document on zoonotic avian influenza pulls existing measures into one place as wild-bird detections hit a record. Pricing and access teams should read it as a signal, not a mandate.
BfArM has listed an urgent field safety notice for Urotech's Renodrain Nephrostomie catheter without describing the problem. It is one of several thin public entries this week, and the gap affects how quality teams respond.
The UK approval of Incyte's ZYNYZ with carboplatin and paclitaxel shows how the recognition route works in practice, while the week's other records show where timelines still diverge.
A new EMA web page sets out expected outcomes of AI across the EU network and a 2021-to-August-2026 timeline. For pharmacovigilance, the detail still has to be read and tested against daily workload.
FDA's early alert on Arrow guidewires and PICC/JACC catheters is one of several detachment-type device notices this week. It is a prompt to test complaint intake and signal triage.
The Oncology Center of Excellence has opened comments on protocol recommendations for first-in-human and limited-experience solid-tumour trials. Here is what is known, what is not, and how to prepare.
The November 2026 MHRA list of ended UK manufacturing and wholesale licences is routine, but recent shortage notices in France, Slovenia and Czechia show why access teams should read it.
MHRA's weekly notice list, three BfArM postings and two Health Canada recalls show how little detail regulators publish and how much work lands on quality teams.
The UK regulator swapped in November 2026 versions of its MS and MANSA registers on 10 November. The update is small, but it matters for supplier checks, as other regulators' news this week shows.
A solvent shortfall in manufacturing could let connectors separate from Intersurgical breathing tubing. Alongside Arrow, Merit and Abiomed actions, it sharpens the case for linking complaint data to manufacturing causes.
Accelerated approval bids on novel biomarkers and EMA's draft assay guideline point the same way: the measurement is now part of the regulatory claim, and teams should treat it like one.
Revision 1 of EMA's draft guideline covers the route from reproductive and lactation data to product information. PV teams should read it now, even though much of the detail is not yet public.
Zentalis says Part 2c enrolment finishes in November and cash lasts into 1H 2028, leaving a defined window between DENALI data and any accelerated approval discussion with the FDA.
DKMA will deactivate its section 29(2) permissions for German-authorised Paracetamol AL 500 mg and 1000 mg suppositories on 12 November, a sign that shortage workarounds are time-limited.
The German regulator has posted an urgent field safety notice for various EPflex guidewires. Its public listing carries no defect detail, so QA teams must work from the advisory itself.
The approval of asundexian for secondary stroke prevention opens a new anticoagulant class in the US. The label details and the EU picture are what regulatory teams need to track next.
The EMA's new document on centrally authorised veterinary medicines is a niche item, but alongside this week's FDA and EMA actions it shows how safety findings become product information.
FDA's Zolgensma probe cites confirmed vector insertional oncogenesis involving GLI1. Every AAV pharmacovigilance team should ask now whether its own malignancy surveillance could detect the same mechanism.
A pilot has become an established service, and the evidence questions in this week's records show why market access teams should treat joint regulator-HTA dialogue as part of planning, not a curiosity.
Spain's AEMPS flags a double-failure risk in some Likorall ceiling lifts, a reminder for PV teams that latent faults and layered safeguards drive many safety signals.
Xencor will meet the FDA in H1 2027 on a possible accelerated approval route for its ENPP3 x CD3 bispecific. The headline number is only a starting point for that discussion.
CMS-3484-P promises fewer administrative requirements, but the available material gives no detail. Italy's AIFA registry updates show what reimbursement paperwork looks like in practice.
The Dutch inspectorate has published a report on its September 2026 visit to Byondis in Nijmegen, but the listing gives no findings. Quality teams should read the document, not the headline.
The regulator has published exclusivity expiry dates for products first authorised globally between 2014 and 2021, giving generic and biosimilar planners a CSV to check against their own models.
As FDA's acting commissioner touts 28 novel rare disease approvals, new CBER and MHRA safety actions show where post-approval vigilance carries the weight.
CMS has made Medicare price negotiation a lasting framework and MHRA-NICE has turned its RWE dialogue from pilot into service. Access teams should respond with standing functions, not one-off projects.
The UK regulator's new plan to embed patients, carers and the public in its decisions lands in a week of safety communications that show where involvement could matter most.
New UK guidance says trial applications relying on non-OECD MAD safety data may be considered, with enhanced assessment in limited cases and a programme of test facility inspections.
Health Canada's Intersurgical Smoothbore recall is a supply problem; AIFA's registry revisions are an administrative one. Both can interrupt access, and teams should plan for each differently.
A $1.25m False Claims Act settlement over disguised commissions lands the same week as device recalls and counterfeit alerts, showing the breadth of the lab compliance perimeter.
A direct final rule says nonclinical tests can include cell-based assays, organs-on-chips and computer models. It mandates no method and leaves evidentiary standards as they were.
CBER is assessing postmarketing malignancy reports and says the neoplasia risk covers both onasemnogene abeparvovec products. Here is what PV teams should take from it.
The camizestrant report shows the JCA is now producing output. Access teams that treat it as a shortcut will lose time to those who treat it as the first input into every national process.
The UK regulator's interim advice on givinostat in Duchenne muscular dystrophy is a precautionary step pending an independent review, with no UK deaths reported so far.
The MHRA's updated page on GCP inspections, with ICH E6(R3) as the reference standard, lands in a week of regulator moves on non-clinical data and early-phase trial review.
The Commission has published a joint clinical assessment on camizestrant (Etcamah), prepared by Austria and Belgium. National pricing and reimbursement still decide access, as Italy's registry updates show.
MHRA's Class 4 notice on a wrong dosing table in all batches of Sandoz's 250/62.5 mg/5 mL suspension shows how document control failures can carry real dosing risk.
An FDA office lists four 2026 priorities and 11 topics for 2027-2028, spanning combination products, EUA, informed consent, paediatric research and orphan designation, and invites comment.
EMA's single assessment of the combined pill ingredients keeps authorisations in place. A routine result still triggers checks on product information, national lists and signal files.
MHRA's interim advice on givinostat, issued with no UK deaths reported, shows the signal can start elsewhere. QPPVs should decide in advance how their systems respond.
EMA has published a Q&A for MAHs and applicants on the CHMP's Article 5(3) nitrosamine opinion. It lands in a week when quality defects and batch signals are again driving safety communications.
Sponsors in the biologics centre's pilot will file components during pre-IND development, each vetted by a QRI before the 30-day review starts. The design tests whether front-loading can speed early trials.
After a pilot, the UK's joint regulator-HTA real-world evidence service has opened its newest application cycle, with application details and an expression-of-interest form now published.
Three Aspire Pharma batches carry an April 2027 expiry when the correct date is 31 October 2026, a labelling error that tests release checks, stock control and recall readiness.
FDA cleared Janssen's subcutaneous amivantamab on single-arm response data in 102 patients. The confirmatory-study obligation is where the regulatory work now sits.
A routine PSUSA outcome ends in maintenance. Alongside other safety items published the same week, it shows how quiet outcomes and active reviews run side by side in PV.
Italian registry forms, US payment codes and state Medicaid policies decide who gets a product, and they change on their own schedule. Market access teams should track them as access events.
A PRAC look at batch-linked allergic reactions to immunoglobulins, plus a week of lot-specific recalls, shows that the batch is often the unit of risk. Most PV systems still treat it as a free-text field.
AABB's first certification under its new quality-management programme assesses the system, not the cellular products. Compliance teams should treat that distinction as a rule, not a footnote.
CMS's CY 2027 final rule pushes accountable care toward value. The records show no direct PV provisions, but the shift matters for how safety signals reach clinicians.
CBER has closed applications after more than 100 submissions and will pick participants by 18 December, testing whether outside experts and rolling review can speed first-in-human trials safely.
Florida's Medicaid coverage and a CE Mark submission for a kit-based test mark two different access tests: state-by-state US payer uptake and EU market entry.
MHRA's weekly roundup names Abbott, Philips, Abiomed and Beckman Coulter but not the problems. Parallel listings in Germany and Canada show the same gap between publication and actionable detail.
New UK guidance describes a risk-proportionate framework for trial applications relying on non-clinical data generated outside the OECD MAD system. Sponsors should check their data packages.
EMA has published Appendix V of the QRD documentation, covering the ADR reporting statement and contact details, but has not specified what changed. Live batch-level safety issues show why it matters.
This week's records show regulator notices that misdescribe, under-describe or are relayed second-hand. Teams that act on summaries are building compliance on sand.
Six PSUSA maintenance outcomes, a safety-label change list and a new QRD Appendix V landed in days. Treat them as one workflow, not as filing noise.
Brussels and Ottawa are stepping up joint work on medical countermeasures, but with no measures published, this week's safety records show where pharmacovigilance pressure is likely to fall.
Arvinas's Q3 update pairs a first-in-human degrader start with planned EU and UK filings for ARV-102, just as ACT EU makes its CTIS pre-submission advice a standing service.
Rhythm's Q3 update combines a 13 October Japanese launch, US uptake and European reimbursement filings. Market access teams should read it alongside Italy's registry moves and Inspire's coding timeline.
A Florida cellular medicine maker is first under AABB's new Quality Management Systems programme, but the certification explicitly leaves its products out of scope.
DG SANTE has listed guidance on clinical evidence for orphan in vitro diagnostics, but the entry's description points to a different IVD classification document. Teams should read the PDF itself.
Compact Medical's removal of nine resuscitator lots, plus a pre-use test fix on 22 more, sits alongside B. Braun and Fresenius Kabi leak cases. All three are quality signals PV teams should be ready to triage.